首页 | 本学科首页   官方微博 | 高级检索  
     


Opioide bei chronischem Arthroseschmerz
Authors:R. Schaefert  P. Welsch  P. Klose  C. Sommer  F. Petzke  W. Häuser
Affiliation:1.Klinik für Allgemeine Innere Medizin und Psychosomatik,Universit?tsklinikum Heidelberg,Heidelberg,Deutschland;2.Stichting Rugzorg Nederland,Ede,Niederlande;3.Abteilung für Natuheilkunde und Integrative Medizin,Kliniken Essen-Mitte,Essen,Deutschland;4.Neurologische Klinik,Universit?tsklinikum Würzburg,Würzburg,Deutschland;5.Schmerz-Tagesklinik und -Ambulanz,Universit?tsmedizin G?ttingen,G?ttingen,Deutschland;6.Klinik und Poliklinik für Psychosomatische Medizin und Psychotherapie,Technische Universit?t München,München,Deutschland;7.Innere Medizin I,Klinikum Saarbrücken gGmbH,Saarbrücken,Deutschland
Abstract:

Background

The efficacy, tolerability and safety of opioid therapy in chronic osteoarthritis (OA) pain is under debate. We updated a Cochrane systematic review on the efficacy and safety of opioids in chronic OA pain published in 2009.

Methods

We screened MEDLINE, Scopus and the Cochrane Central Register of Controlled Trials (CENTRAL) up until October 2013, as well as reference sections of original studies and systematic reviews of randomized controlled trials (RCTs) of opioids in chronic osteoarthritis (OA) pain. We included double-blind randomized placebo-controlled studies lasting ≥?4 weeks. Using a random effects model, absolute risk differences (RD) were calculated for categorical data and standardized mean differences (SMD) for continuous variables.

Results

We included 20 RCTs with 33 treatment arms and 8545 participants. Median study duration was 12 (4–24) weeks. Oxycodone and tramadol were each tested in six studies; buprenorphine, hydromorphone, morphine and tapentadol each in two studies and codeine, fentanyl and oxymorphone in one study each. Results are reported with 95?% confidence intervals (CIs). Opioids were superior to placebo in reducing pain intensity (SMD ??0.22 [??0.28, ??0.17], p?

Conclusion

Opioids were superior to placebo in terms of efficacy and inferior in terms of tolerability. The effect sizes of average reduction in pain intensity and physical disability were small. Opioids and placebo did not differ in terms of safety. The conclusion on the safety of opioids compared to placebo is limited by the low number of SAE and deaths. Short-term opioid therapy may be considered in selected chronic OA pain patients. No current evidence-based guideline recommends opioids as first-line treatment option for chronic OA pain. To provide superior evidence for future treatment guidelines, RCTs must directly compare existing pharmacological and nonpharmacological therapies and administer these in various combinations and sequences.The English full-text version of this article is freely available at SpringerLink (under “Supplemental”).
Keywords:
本文献已被 SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号